{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:35:30Z","timestamp":1792787730205,"version":"4.5.0"},"reference-count":14,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"CASI Pharmaceuticals, Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/02xbbj940","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Melphalan formulated with modified cyclodextrin (\u03b2-cyclodextrin sulfobutyl ether sodium [BSES]) is widely used before autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) because of its favorable solubility and stability versus conventional melphalan, but the efficacy and safety data on Chinese patients with MM who subsequently underwent ASCT are still limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this prospective, open-label, non-randomized, interventional study, a total of 67 MM patients who were eligible for ASCT were enrolled and assigned to receive 200 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      of Melphalan in two divided doses of 100 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on Days \u22123 and \u22122 before ASCT on Day 0. We evaluated the efficacy, safety and pharmacokinetics (PK) of a prolonged infusion of high-dose BSES-melphalan as the conditioning treatment in the patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 67 patients received melphalan with the median infusion time of 136 min. All patients achieved myeloablation with a median time of 5 days. Median time to neutrophil and platelet engraftments was 11 and 12 days after ASCT, respectively. Within the 65 evaluable patients, 18 patients (27.7%) achieved stringent complete response, 21 (32.3%) achieved complete response, 18 (27.7%) achieved very good partial response, and 3 (4.6%) achieved partial response. No treatment-related mortality (TRM) or adverse events leading to study withdrawal were identified. Prolonged infusion resulted in a lower C\n                      <jats:sub>max<\/jats:sub>\n                      but comparable AUCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High-dose BSES-melphalan as a conditioning medicine is effective and safe in Chinese patients with MM before ASCT. Prolonging infusion duration may improve the safety without compromising efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251336172","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T03:57:15Z","timestamp":1745899035000},"page":"1280-1288","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety, effectiveness and pharmacokinetics of high-dose propylene glycol-free melphalan (EVOMELA) with a prolonged infusion as myeloablative conditioning in Chinese multiple myeloma patients undergoing autologous stem cell transplantation: A prospective phase iv study"],"prefix":"10.1177","volume":"32","author":[{"given":"Fengrong","family":"Wang","sequence":"first","affiliation":[{"name":"Hematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Blood Diseases, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[{"name":"Beijing Chaoyang Hospital, Capital Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[{"name":"The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Fu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[{"name":"Fujian Medical University Union Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchuan","family":"Chen","sequence":"additional","affiliation":[{"name":"West China Hospital of Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital, Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2233-3757","authenticated-orcid":false,"given":"Kaiyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Hematology Department, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2006.26.1.23"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2007.00280.x"},{"key":"e_1_3_3_4_2","unstructured":"US Food & Drugs Administration. EVOMELA melphalan for injection. Highlights of prescribing information 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207155s001lbl.pdf"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.08.026"},{"key":"e_1_3_3_6_2","first-page":"353","article-title":"Chinese Guidelines of autologous stem cell transplantation for multiple myeloma (2021)","volume":"42","author":"Plasma Cell Disease Group CSoH, Chinese Medical Association, Chinese Myeloma Committee-Chinese Hematology Association","year":"2021","unstructured":"Plasma Cell Disease Group CSoH, Chinese Medical Association, Chinese Myeloma Committee-Chinese Hematology Association. Chinese Guidelines of autologous stem cell transplantation for multiple myeloma (2021). Zhonghua Xue Ye Xue Za Zhi 2021; 42: 353\u2013357.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20162"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20163"},{"key":"e_1_3_3_9_2","unstructured":"World Health Organization. WHO handbook for reporting results of cancer treatment. 1979 https:\/\/apps.who.int\/iris\/handle\/10665\/37200."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(99)00280-7"},{"key":"e_1_3_3_11_2","first-page":"28","article-title":"[Short-term efficacy and side effects of melphalan hydrochloride for injection in autologous hematopoietic stem cell transplantation and its sequential chimeric antigen receptor cell therapy for hematological malignancies; in Chinese","volume":"28","author":"Ming X","year":"2022","unstructured":"Ming X, Yu Q, Zhang X, et al. [Short-term efficacy and side effects of melphalan hydrochloride for injection in autologous hematopoietic stem cell transplantation and its sequential chimeric antigen receptor cell therapy for hematological malignancies; in Chinese. . J Int Intensive Med 2022; 28: 28\u201331.","journal-title":". J Int Intensive Med"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.120"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.6028"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/2397847320978633"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0302-6"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251336172","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251336172","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251336172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:56:17Z","timestamp":1790330177000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251336172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10781552251336172"],"URL":"https:\/\/doi.org\/10.1177\/10781552251336172","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}